Dengue Vaccines and Antibody-Dependent Enhancement (ADE)

On 8th June 2026, Brazil suspended the use of the Butantan-DV dengue vaccine after adverse events were reported during its dengue vaccination campaign.

  • The incident has raised concerns for India, as DengiAll, India's upcoming dengue vaccine developed by Panacea Biotec, is based on a similar vaccine platform.
  • Both Butantan-DV and DengiAll are live-attenuated tetravalent dengue vaccines, designed to provide protection against all four dengue virus serotypes (DENV-1, DENV-2, DENV-3, and DENV-4).
  • A major concern with dengue vaccination is Antibody-Dependent Enhancement (ADE), a phenomenon in which low levels of cross-reactive antibodies fail to neutralize the virus and instead enhance infection, increasing ....
Do You Want to Read More?
Subscribe Now
To get access to detailed content
Buy August 2026 Issue

Already a Member? Login here

Take Annual Subscription and get the following Advantage
The annual members of the Civil Services Chronicle can read the monthly content of the magazine as well as the Chronicle magazine archives.
Readers can study all the material before the last six months of the Civil Services Chronicle monthly issue in the form of Chronicle magazine archives.
Be an Annual Subscriber

Related Content